Rhumbline Advisers purchased a new position in shares of Senseonics Holdings Inc (NYSEAMERICAN:SENS) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 62,158 shares of the company’s stock, valued at approximately $255,000.

A number of other large investors have also added to or reduced their stakes in SENS. Gilder Gagnon Howe & Co. LLC bought a new position in Senseonics in the 2nd quarter valued at about $74,936,000. Millennium Management LLC increased its holdings in Senseonics by 43.5% in the 1st quarter. Millennium Management LLC now owns 1,387,566 shares of the company’s stock valued at $4,163,000 after buying an additional 420,358 shares during the period. Broadview Advisors LLC bought a new position in Senseonics in the 2nd quarter valued at about $2,774,000. Raymond James Financial Services Advisors Inc. increased its holdings in Senseonics by 19.6% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 651,481 shares of the company’s stock valued at $2,678,000 after buying an additional 106,679 shares during the period. Finally, Emerald Mutual Fund Advisers Trust bought a new position in Senseonics in the 2nd quarter valued at about $1,531,000. 30.66% of the stock is currently owned by institutional investors and hedge funds.

SENS opened at $4.34 on Monday. Senseonics Holdings Inc has a 1-year low of $2.36 and a 1-year high of $5.29. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.93 and a quick ratio of 2.81.

Senseonics (NYSEAMERICAN:SENS) last posted its quarterly earnings results on Wednesday, August 8th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.09). Senseonics had a negative net margin of 828.76% and a negative return on equity of 406.72%. The company had revenue of $3.62 million during the quarter, compared to analyst estimates of $3.87 million. During the same quarter in the previous year, the business posted ($0.12) earnings per share. The company’s revenue for the quarter was up 345.1% on a year-over-year basis. sell-side analysts predict that Senseonics Holdings Inc will post -0.54 earnings per share for the current year.

Several equities analysts have commented on SENS shares. Craig Hallum started coverage on shares of Senseonics in a report on Monday, June 11th. They issued a “buy” rating and a $7.00 target price on the stock. BTIG Research reissued a “buy” rating and issued a $5.00 target price on shares of Senseonics in a report on Thursday, June 7th. Dougherty & Co started coverage on shares of Senseonics in a report on Friday, August 24th. They issued a “buy” rating and a $6.00 target price on the stock. Finally, Raymond James raised their target price on shares of Senseonics from $4.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, June 22nd. Six investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $6.00.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Featured Story: Short Selling – Explanation For Shorting Stocks

Want to see what other hedge funds are holding SENS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Senseonics Holdings Inc (NYSEAMERICAN:SENS).

Institutional Ownership by Quarter for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.